Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

被引：5
|
作者：
Patel, Saagar N. [1 ]
Camacci, Mona L. [1 ]
Bowie, Esther M. [1 ]
机构：
[1] Penn State Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA
来源：
CASE REPORTS IN OPHTHALMOLOGY | 2022年 / 13卷 / 01期
关键词：
Fibroblast growth factor receptor; Fibroblast growth factor receptor retinopathy; Optical coherence tomography; Mitogen-activated protein kinase; Mitogen-activated protein kinase kinase associated retinopathy;
D O I：
10.1159/000519275
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.
引用
收藏
页码：57 / 63
页数：7
相关论文
共 50 条
  • [1] Pan fibroblast growth factor receptor inhibitor associated retinopathy
    Paris, Arianna
    Bodaghi, Bahram
    Touhami, Sara
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (03) : NP66 - NP71
  • [2] Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
    Parikh, Deep
    Eliott, Dean
    Kim, Leo A.
    JAMA OPHTHALMOLOGY, 2020, 138 (10) : 1101 - 1103
  • [3] Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor
    Day, H. Russell
    Finn, Avni P.
    JOURNAL OF VITREORETINAL DISEASES, 2023, 7 (04) : 352 - 355
  • [4] Dose-Dependent and Reversible Serous Retinal Detachments in Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
    Parikh, Deep
    Patel, Veshesh
    Yannuzzi, Nicolas
    Greenstein, Scott H.
    Eliott, Dean
    Kim, Leo A.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2023, 54 (06): : 368 - 370
  • [5] Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
    Francis, Jasmine H.
    Harding, James J.
    Schram, Alison M.
    Canestraro, Julia
    Haggag-Lindgren, Dianna
    Heinemann, Murk
    Kriplani, Anuja
    Jhaveri, Komal
    Voss, Martin H.
    Bajorin, Dean
    Abou-Alfa, Ghassan K.
    Iyer, Gopa
    Drilon, Alexander
    Rosenberg, Jonathan
    Abramson, David H.
    JAMA OPHTHALMOLOGY, 2021, 139 (10) : 1126 - 1130
  • [6] Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
    Zhou, Zhan
    Chen, Xiaojuan
    Fu, Ying
    Zhang, Ye
    Dai, Shuyan
    Li, Jun
    Chen, Lin
    Xu, Guangyu
    Chen, Zhuchu
    Chen, Yongheng
    CHEMICAL COMMUNICATIONS, 2019, 55 (42) : 5890 - 5893
  • [7] Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
    Jeffrey Ahn
    Justin Moyers
    John Wong
    Chung-Tsen Hsueh
    Experimental Hematology & Oncology, 8
  • [8] Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
    Ahn, Jeffrey
    Moyers, Justin
    Wong, John
    Hsueh, Chung-Tsen
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [9] Novel inhibitor for fibroblast growth factor receptor tyrosine kinase
    Kammasuda, Naparat
    Boonyarat, Chantana
    Tsunoda, Satoshi
    Sakurai, Hiroaki
    Saiki, Ikuo
    Grierson, David S.
    Vajragupta, Opa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (17) : 4812 - 4818
  • [10] Pemigatinib Fibroblast growth factor receptor inhibitor Treatment of cholangiocarcinoma
    Franco, B.
    Clarke, P.
    Carotenuto, P.
    DRUGS OF THE FUTURE, 2019, 44 (12) : 923 - 932
12345